Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica

Immunotherapy is a specific treatment for allergic diseases. Unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. This is a prospective double-blind placebo controlled study with two arms of treatment: placebo and active.

Inclusion criteria

• Informed consent, signed by the subject
• Positive clinical history of rhinitis/rhinoconjunctivitis allergy to Parietaria pollen
• Patient of both gender aged from 18 up to 55
• Diagnosed Sensitivity to Parietaria pollen base on:

Positive Nasal provocation test Positive prick test to P. Judaica Specific IgE to P.Judaica >0,7KU/L

• Patients who are able to comply with the dose regime

Exclusion criteria

• Relevant sensitivity to another perenne allergen
• Patient with asthma
• Use of immunotherapy during the last four years
• Treatment with B. Blocking agents
• Patient suffering from some pathology in which adrenaline was contraindicated
• Subject suffers from a serious medical condition, which would interference the treatment and follow up of the subject in the study
• Subject suffers from autoimmune disease(thyroiditis, lupus, etc.)
• Conditions in which the patient can not offer full co-operation nad significant psychiatric disturbance.
• Intolerance to aspirin
• Pregnant women or with pregnancy risk and brest-feeding